Dinutuximab beta in the treatment of high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028716
Abstract: Abstract Despite therapeutic advances, high-risk neuroblastoma is still associated with a poor long-term prognosis. Immunotherapy with the anti-GD2 antibody dinutuximab beta has recently been added to the standard of care for patients with high-risk neuroblastoma… read more here.
Keywords: beta; risk neuroblastoma; dinutuximab beta; high risk ... See more keywords
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1082771
Abstract: Prognosis in children with refractory and relapsed high-risk neuroblastoma is poor. Only a minority of patients obtain remission when treated with second-line chemotherapy regimens. Chemotherapy combined with anti-GD2 antibodies has previously been shown to increase… read more here.
Keywords: relapsed refractory; dinutuximab beta; patients relapsed; response ... See more keywords